{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T23:11:11Z","timestamp":1721085071379},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The treatment of lymphomas has undergone a shift in the last few decades, from traditional cytotoxic chemotherapy toward immune-targeting agents that supplement or, in some cases, even supplant direct tumor killing with activation of antitumor systemic immunity. Since the introduction of the first known immunomodulatory modality, allogeneic hematopoietic cell transplantation, multiple immunotherapeutic approaches have been developed including monoclonal antibodies (mABs), antibody-drug conjugates, bispecific T-cell engagers, checkpoint inhibitors, small molecule inhibitors, chimeric antigen receptor (CAR) T-cell therapies, and vaccines. Many of these agents, either as monotherapies or as a component of a combination strategy, have shown impressive results, combining efficacy with tolerability. Immunotherapy ranging from mABs to checkpoint inhibitors and CAR T-cell therapy are now integrated into lymphoma treatment from the earliest lines of therapy to the relapsed and refractory setting for both Hodgkin (HL) and non-Hodgkin lymphoma (NHL). Although further studies are needed to improve our understanding of the unique side effects of immunomodulation, to determine the optimal sequence and combinations of these agent with targeted therapies and standard chemotherapy, and to identify predictive biomarkers, they clearly represent a growing list of treatment options for both HL and NHL and an important step on our road toward cure of these diseases.<\/jats:p>","DOI":"10.1182\/hematology.2020000146","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T03:45:09Z","timestamp":1607139909000},"page":"598-605","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy with drugs"],"prefix":"10.1182","volume":"2020","author":[{"given":"Yun","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine S.","family":"Diefenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"2","key":"2020121621263894500_B1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","article-title":"A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies","volume":"34","author":"Tobinai","year":"2017","journal-title":"Adv Ther"},{"issue":"4","key":"2020121621263894500_B2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000381524","article-title":"Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-Hodgkin\u2019s lymphomas: a glycoengineered type II CD20 antibody","volume":"38","author":"Goede","year":"2015","journal-title":"Oncol Res Treat"},{"issue":"14","key":"2020121621263894500_B3","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"2020121621263894500_B4","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"issue":"31","key":"2020121621263894500_B5","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020121621263894500_B6","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1080\/1042819021000040044","article-title":"Recurrent B-cell neoplasms after rituximab therapy: an immunophenotypic and genotypic study","volume":"43","author":"Chu","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2020121621263894500_B7","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/annonc\/mdy056","article-title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"29","author":"Jurczak","year":"2018","journal-title":"Ann Oncol"},{"issue":"15 suppl","key":"2020121621263894500_B8","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.1200\/JCO.2019.37.15_suppl.7521","article-title":"Update of the single-arm phase II L-MIND study of MOR208 + lenalidomide (LEN) in relapsed\/refractory diffuse large B-cell lymphoma (R-R DLBCL): response rates in patient subgroups with poor prognosis","volume":"37","author":"Maddocks","year":"2019","journal-title":"J Clin Oncol"},{"issue":"18","key":"2020121621263894500_B9","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"2020121621263894500_B10","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"2020121621263894500_B11","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia"},{"key":"2020121621263894500_B12","first-page":"2821","article-title":"Addition of polatuzumab vedotin to bendamustine and rituximab (BR) improves outcomes in transplant-ineligible patients with relapsed\/refractory (R\/R) diffuse large b-cell lymphoma (DLBCL) versus BR alone: results from a randomized phase 2 study","volume":"130","author":"Sehn","year":"2017","journal-title":"Blood"},{"issue":"15 suppl","key":"2020121621263894500_B13","doi-asserted-by":"crossref","first-page":"TPS7571","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7571","article-title":"POLARIX: a phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL","volume":"37","author":"Tilly","year":"2019","journal-title":"J Clin Oncol"},{"issue":"18","key":"2020121621263894500_B14","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA approval: blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"2020121621263894500_B15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2020121621263894500_B16","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/cts.12535","article-title":"A preclinical population pharmacokinetic model for anti-CD20\/CD3 T-cell-dependent bispecific antibodies","volume":"11","author":"Ferl","year":"2018","journal-title":"Clin Transl Sci"},{"key":"2020121621263894500_B17","article-title":"CD20-TCB in relapsed or refractory non-Hodgkin lymphoma: durable complete responses and manageable safety observed at clinically relevant doses in phase I dose escalation","author":"Dickinson"},{"issue":"suppl 1","key":"2020121621263894500_B18","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood-2019-123949","article-title":"Dual CD20-targeted therapy with concurrent CD20-TCB and obinutuzumab shows highly promising clinical activity and manageable safety in relapsed or refractory B-cell non-Hodgkin lymphoma: preliminary results from a phase Ib trial","volume":"134","author":"Morschhauser","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621263894500_B19","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1182\/blood-2019-122451","article-title":"Clinical activity of REGN1979, a bispecific human, anti-CD20 x anti-CD3 antibody, in patients with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (B-NHL)","volume":"134","author":"Bannerji","year":"2019","journal-title":"Blood"},{"issue":"17","key":"2020121621263894500_B20","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2020121621263894500_B21","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin lymphoma with reduced \u03b22M\/MHC class I expression is associated with inferior outcome independent of 9p24.1 status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"21","key":"2020121621263894500_B22","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2006.10.0917","article-title":"HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin\u2019s lymphoma","volume":"25","author":"Diepstra","year":"2007","journal-title":"J Clin Oncol"},{"issue":"19","key":"2020121621263894500_B23","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"KEYNOTE-087: phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"14","key":"2020121621263894500_B24","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2020121621263894500_B25","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2020.38.15_suppl.8005","article-title":"KEYNOTE-204: randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R\/R cHL)","volume":"38","author":"Kuruvilla","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020121621263894500_B26","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol."},{"issue":"11","key":"2020121621263894500_B27","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"issue":"13","key":"2020121621263894500_B28","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"Twa","year":"2014","journal-title":"Blood"},{"issue":"34","key":"2020121621263894500_B29","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020121621263894500_B30","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/ng.3370","article-title":"Genomic analysis of mycosis fungoides and S\u00e9zary syndrome identifies recurrent alterations in TNFR2","volume":"47","author":"Ungewickell","year":"2015","journal-title":"Nat Genet"},{"issue":"1","key":"2020121621263894500_B31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"},{"key":"2020121621263894500_B32","first-page":"bjh.16756","article-title":"Checkpoint blockade treatment sensitises relapsed\/refractory non-Hodgkin lymphoma to subsequent therapy","author":"Carreau","year":"2020","journal-title":"Br J Haematol"},{"issue":"25","key":"2020121621263894500_B33","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol"},{"issue":"14","key":"2020121621263894500_B34","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"29","key":"2020121621263894500_B35","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15","key":"2020121621263894500_B36","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2020121621263894500_B37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s40425-018-0457-0","article-title":"PI3K\u03b1\/\u03b4 inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity","volume":"6","author":"Carnevalli","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"18","key":"2020121621263894500_B38","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9980","key":"2020121621263894500_B39","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"2020121621263894500_B40","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/598\/1795093\/hem2020000146c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/598\/1795093\/hem2020000146c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T18:16:55Z","timestamp":1608315415000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/598\/474297\/Immunotherapy-with-drugs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020000146","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}